Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ASPH | Q12797 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16528992 | 0.93 | ALDH1A1 (0.50) | CFTRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL28747469 | 0.85 | NOTUM (0.48) | KDM4EALDH1A1HPGDHSD17B10NOTUM | |
| SCHEMBL29702028 | 0.85 | NOTUM (0.48) | KDM4EALDH1A1HPGDHSD17B10NOTUM | |
| SCHEMBL23040875 | 0.84 | CFTR (0.45) | CFTRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29417318 | 0.84 | CFTR (0.45) | CFTRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23040878 | 0.80 | CFTR (0.68) | CFTRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29398417 | 0.80 | NOTUM (0.44) | KDM4EALDH1A1NOTUMKEAP1ASPH | |
| SCHEMBL22578998 | 0.80 | CFTR (0.52) | CFTRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22203101 | 0.80 | NOTUM (0.44) | KDM4EALDH1A1NOTUMKEAP1ASPH | |
| SCHEMBL21666169 | 0.79 | CFTR (0.51) | CFTRKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473291-B2 | Benzodiazepine compound, preparation method therefor, and use thereof in medicine | WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) | 2025-11-18 | — | — | US | disclosed |
| US-20220348549-A1 | QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-11-03 | — | — | US | disclosed |
| US-20220324867-A1 | BENZODIAZEPINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) | 2022-10-13 | — | — | US | disclosed |
| EP-4021895-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-3992194-A1 | BENZODIAZEPINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | West China Hospital, Sichuan University (CN) | 2022-05-04 | — | — | EP | disclosed |
| CN-114144401-A | Novel quinazoline compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-112142746-B | Benzodiazepine compound, preparation method and medical application thereof | 四川大学华西医院 | 2021-09-24 | — | — | CN | disclosed |
| WO-2021037868-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021037868-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-04 | — | — | WO | disclosed |
| CN-112142746-A | Benzodiazepine compound, preparation method and medical application thereof | 四川大学华西医院 | 2020-12-29 | — | — | CN | disclosed |
| WO-2017192304-A1 | ARYLCARBOXAMIDES AND USES THEREOF | INCEPTION 1, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006062982-A2 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324867-A1 | BENZODIAZEPINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | GABRA1, GABRA4, GABRR1 | CFTR 2279/4885KDM4E 833/4885ALDH1A1 1224/4885 |
| US-20220348549-A1 | QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HAVCR2, RECQL, SLC10A1 | CFTR 619/4885KDM4E 2808/4885ALDH1A1 713/4885 |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | CFTR 2306/4885KDM4E 1734/4885ALDH1A1 2027/4885 |
| US-12473291-B2 | Benzodiazepine compound, preparation method therefor, and use thereof in medicine | GABRA1, GABRA4, GABRR1 | CFTR 2279/4885KDM4E 833/4885ALDH1A1 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.